Probiotics for maintenance of remission in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Fagbemi, Andrew O ^b   Thomas, Adrian G ^b   Akobeng, Anthony Kwaku ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b BOOTH HALL CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; PROBIOTIC AGENT; STEROID;

CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; ENDOSCOPY; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; REMISSION; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 55049095899     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007443     Document Type: Review

References (22)

1. Campieri 1998 Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or possible therapeutic alternative?. Gastroenterology 1998;116(5):1246-60.
2. Cui 2004 Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al.Effects of probiotics on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004;10(10):1521-5.
3. Dieleman 2003 Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, et al.Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003;52(3):370-6.
4. Fabia 1993 Fabia R, Ar'Rajab A, Johansson ML, Willen R, Andersson R, Molin G, et al.The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic-induced colitis in the rat. Scand J Gastroenterol 1993;28(2):155-62.
5. Gionchetti 2000 Gionchetti P, Rizzzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzochi G, et al.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119(2):305-9.
6. Guslandi 2003 Guslandi M, Giollo P, Testoni PA. A pilot trial of saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15(6):697-8.
7. Hanauer 2004 Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126(6):1582-92.
8. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
9. Higgins 2005 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, 2005; Issue 3.
10. Jadad 1996 Jadad AR, MooreRA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996;17(1):1-12.
11. Kato 2004 Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, et al.Randomised placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004;20(10):1133-41.
12. Kennedy 2000 Kennedy RJ, Hoper M, Deodhar K, Kirk SJ, Gardiner KR. Probiotic therapy fails to improve gut permeability in a hapten model of colitis. Scand J Gastroenterol 2000;35(12):1266-71.
13. Kruis 1997 Kruis W, Schultz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of oral Escherichia coli preparation and mesalazine inmaintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11(5):853-8.
14. Kruis 2004 Kruis W, Fric P, Pokrotnieks J, Lukas M, Kascak M, Kamm MA, et al.Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-23.
15. Madsen 1999 Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116(5):1107-14.
16. Madsen 2001 Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al.Probiotic bacteria enchance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121(3):580-91.
17. Rembacken 1999 Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999;354(9179):635- 9.
18. Sartor 2004 Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics and prebiotics. Gastroenterology 2004;126(6):1620-33.
19. Schultz 2002 Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, et al.Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002;8(2):71-80.
20. Shibolet 2002 Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, et al.Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 2002;8(6):399-406.
21. Walmsley 1998 Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43(1):29-32.
22. Zocco 2006 Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al.Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23(11):1567-74.